Scope, Claims, and US Patent Landscape for US 9,549,909 (Fenfluramine + Stiripentol + Valproate + Clobazam for Dravet Syndrome)
US 9,549,909 is a US method-of-treatment patent with claim scope focused on oral polytherapy for Dravet syndrome using fenfluramine (or a pharmaceutically acceptable salt) combined with stiripentol, valproate, and clobazam. The independent claim is a quadruple regimen, and dependent claim 2 narrows fenfluramine dosing to 0.5 mg/kg/day to 0.01 mg/kg/day. Claim 3 adds a liquid formulation pathway for the fenfluramine component plus the same dosing band and oral administration of the other three agents. The practical IP takeaway is that the patent is not a composition claim and does not cover injectable or non-oral delivery by its face, and it is structurally vulnerable to design-arounds that omit one of the four active ingredients, change the delivery route, or escape the fenfluramine dosing range as claimed.
What is US Patent 9,549,909 and what does it claim for Dravet syndrome?
Core subject matter. The claims recite methods of ameliorating seizures in patients diagnosed with Dravet syndrome. The method consists of oral administration of four active agents in combination:
- fenfluramine (or a pharmaceutically acceptable salt)
- stiripentol (or a pharmaceutically acceptable salt)
- valproate (or a pharmaceutically acceptable salt)
- clobazam (or a pharmaceutically acceptable salt)
The therapeutic target is seizure amelioration in Dravet syndrome, which is a method-of-use framing.
Independent claim 1 scope: what combinations are required?
Claim 1 requires all four components and all are administered orally:
- Fenfluramine (or salt) is orally administered at an effective dose.
- Stiripentol (or salt) is orally administered at an effective dose.
- Valproate (or salt) is orally administered at an effective dose.
- Clobazam (or salt) is orally administered at an effective dose.
- Result: seizures are ameliorated.
Implications for scope.
- The claim is an all-elements regimen. Omission of any one drug is a direct path to non-infringement against claim 1.
- Route is constrained by “orally administering” each active. A regimen using, for example, enteral tube delivery may still be “oral” depending on claim construction, but parenteral dosing is excluded by the claim language.
- The claim is not limited to a particular fenfluramine formulation type in claim 1 (only claim 3 introduces “liquid formulation” as part of fenfluramine).
Dependent claim 2: what dose band for fenfluramine is protected?
Claim 2 narrows claim 1 by specifying fenfluramine dose:
- fenfluramine dose: 0.5 mg/kg/day to 0.01 mg/kg/day
Implications for scope.
- The dosing band is a strong numeric limiter. A regimen using fenfluramine outside that band is outside claim 2 if the dosing is not “within” the range.
- The band is broad (two orders of magnitude). That increases practical coverage across many clinical dose adjustments, but it still leaves risk for therapies that use fenfluramine at or near dosing levels above 0.5 mg/kg/day or at very low “maintenance” levels below 0.01 mg/kg/day.
Dependent claim 3: what additional formulation feature is protected?
Claim 3 requires:
- A liquid formulation comprised of effective dose of fenfluramine (or salt)
- Oral administration of stiripentol, valproate, clobazam
- Fenfluramine dose specified at 0.5 mg/kg/day to 0.01 mg/kg/day
- Result: seizure amelioration
Implications for scope.
- Claim 3 is a formulation-type dependent claim, but only for fenfluramine. It does not explicitly require the other three drugs to be liquids.
- “Liquid formulation comprised of” is likely to capture oral liquid preparations and suspensions/solutions, depending on construction. It does not, by its face, capture solid oral dosage forms for fenfluramine (tablets/capsules) unless those are considered “liquid formulation” by construction (unlikely).
How strong is the patent estate around US 9,549,909 for fenfluramine-based Dravet therapy?
Claim posture. US 9,549,909 is not a broad “fenfluramine for Dravet” claim on its face. Its novelty pressure is tied to:
- the combination of four specific agents, and
- the oral regimen requirement, and
- in dependent claims, a fenfluramine dose window and liquid fenfluramine format.
Where strength typically comes from in this claim structure
- Combination regimens can be defensible if prior art did not disclose the full set of drugs together for Dravet seizure amelioration in a manner that would render the regimen obvious.
- Numeric dose ranges and route and formulation limitations can improve validity.
Where vulnerabilities typically appear
- Quadruple-therapy disclosures in prior art (or published clinical practices) can narrow inventive step.
- If fenfluramine’s Dravet use and concomitant use with at least some standard adjunct antiseizure therapies were known, the remaining inventiveness turns on whether all four were disclosed in a single teaching.
- For dependent claims, if the dose range or “liquid formulation” were taught in earlier disclosures, those dependent limitations can also fail novelty.
Practical enforceability.
- If a competitor product uses fenfluramine with Dravet but excludes stiripentol, excludes valproate, or excludes clobazam, claim 1 is not implicated.
- If it uses solid oral fenfluramine rather than a liquid formulation, claim 3 is not implicated.
- If it uses fenfluramine outside 0.5 to 0.01 mg/kg/day, claim 2 is not implicated.
What is the likely claim construction for “ameliorating seizures” and “diagnosed with Dravet syndrome”?
“Diagnosed with Dravet syndrome.”
- This ties infringement to patient selection. A method practiced on a person without Dravet diagnosis does not fit the claim narrative.
- In litigation, “diagnosed” typically implicates clinician diagnosis and records, not merely suspected disease.
“Ameliorating seizures.”
- Courts generally treat outcome language as requiring some measurable improvement, but not necessarily elimination.
- For infringement, the technical evidence usually focuses on seizure frequency reduction or clinically accepted seizure outcome measures consistent with “amelioration.”
How does US 9,549,909 compare with other patent types (composition, product, exclusivity)?
Method-of-use vs composition
US 9,549,909 is a method claim. It does not claim a formulation of fenfluramine per se, nor does it broadly claim “fenfluramine composition” for Dravet.
Effect on design-around
- A company can potentially market a fenfluramine product while avoiding infringement by not practicing the claimed regimen (or by using a non-liquid formulation for claim 3 and/or dosing outside claim 2).
- Regulators and labeling may not control infringement, but labeling often influences standard-of-care behavior and therefore risk.
Regulatory exclusivity vs patent coverage
Drug marketing authorization and data exclusivity do not automatically map to method-of-use patent exposure. For freedom-to-operate, the key is whether a commercial and clinical regimen is likely to be practiced as claimed.
What patents could cover adjacent aspects (dose, salts, formulations, and co-therapy) around 9,549,909?
Even without a full file history or the broader family mapping, the claim grammar suggests adjacent coverage areas commonly present in the same patent portfolio or related prosecution:
1) Fenfluramine “salt” and dose form patents
US 9,549,909 covers “fenfluramine or pharmaceutically acceptable salt thereof,” but it does not specify which salt or specific formulation besides the “liquid formulation” label for claim 3.
Adjacent patents often include:
- specific salt forms,
- stabilization/vehicle compositions for liquid dosage forms,
- manufacturing methods for liquid fenfluramine.
2) Concomitant antiseizure therapy interaction patents
The quadruple regimen is the distinctive element. Other patents around the space often cover:
- two-drug combinations (fenfluramine + clobazam, fenfluramine + valproate, etc.),
- pediatric co-therapy protocols,
- dosing schedules and titration algorithms.
3) Method-of-use variants
Expect method-of-use claims that shift:
- the target seizure endpoint (frequency vs severity),
- the patient subset (age ranges, seizure type, genotype-based subsets),
- the regimen duration (initiation after failure of prior therapies).
When does US 9,549,909 lose exclusivity? How long does patent protection last in the US?
A complete “when” requires the actual US filing date, priority date, and maintenance status. Those facts are not included in the prompt.
What can be stated from the claim only: the question of loss of exclusivity depends on:
- patent term under US law (including potential adjustments),
- expiration date tied to priority,
- whether maintenance fees were paid.
No actionable expiration date can be produced from the claim language alone.
What generic or biosimilar entry risks exist for this claim?
Small molecule generic risk model
Because the patent is a method-of-treatment for a specific drug regimen:
- A generic fenfluramine manufacturer does not automatically infringe unless it induces or performs the claimed method in the US.
- Infringement risk increases if marketing, labeling, and clinical practice converge on the claimed quadruple oral regimen with the claimed fenfluramine dosing and, for claim 3, liquid fenfluramine.
How to design around the claims
Potential design-arounds implied by the claim elements:
- Omit one co-administered agent: remove stiripentol or valproate or clobazam.
- Change route: avoid “orally administering” for one component (parenteral or other routes).
- Change fenfluramine dosing band: operate outside 0.01 to 0.5 mg/kg/day.
- Use non-liquid fenfluramine: avoid “liquid formulation” if claim 3 is asserted.
What are the commercial implications if 9,549,909 is asserted?
If asserted against a fenfluramine entrant:
- The disputed issue is often whether the competitor’s product is used in the claimed regimen, not whether the product contains the active ingredient.
- Litigation typically targets induced infringement theories tied to labeling and promotional materials, and to real-world dosing patterns.
If asserted against an incumbent:
- A competitor could face an injunction risk if it practices or induces the claimed regimen within the jurisdiction.
What litigation factors typically matter for method-of-use Dravet patents like this?
Key infringement and validity factors that usually decide these disputes:
- Claim construction of “liquid formulation” and “orally administering.”
- Evidence that prescribers administer the full quadruple regimen.
- Evidence that fenfluramine dosing is within 0.5 to 0.01 mg/kg/day.
- Prior art disclosures that teach the same combination (all four drugs) and the same oral regimen for Dravet.
No case-specific docket data is provided in the prompt, so no assertion-level timeline can be generated.
Key Takeaways
- US 9,549,909 is a method-of-treatment patent for Dravet syndrome requiring oral administration of four drugs together: fenfluramine + stiripentol + valproate + clobazam.
- Claim 1 protects the full quadruple regimen at effective doses.
- Claim 2 adds a fenfluramine dose band: 0.5 mg/kg/day to 0.01 mg/kg/day.
- Claim 3 adds fenfluramine as a liquid formulation with the same dosing band.
- Infringement risk for entrants is driven by whether real-world practice (and any labeling/marketing) uses the exact combination, oral route, and (for dependent claims) the numeric fenfluramine dose range and liquid format.
- Design-arounds are structurally available by changing regimen completeness, route, dose band, or fenfluramine formulation type.
FAQs
-
Does US 9,549,909 require all four drugs to be given at the same time or can they be staggered?
The claim reads on a method comprising administration of each drug; timing is not specified in the provided claim text.
-
Can a competitor avoid claim 3 by switching fenfluramine from liquid to tablet/capsule?
Claim 3 explicitly requires a “liquid formulation” comprised of fenfluramine (or salt).
-
Would fenfluramine dosing above 0.5 mg/kg/day avoid infringement of claim 2?
Claim 2’s protected dose range is limited to 0.5 to 0.01 mg/kg/day.
-
If a patient is treated with fenfluramine + stiripentol + valproate but not clobazam, does claim 1 apply?
Claim 1 requires clobazam in addition to the other three.
-
Is US 9,549,909 an Orange Book-listed patent tied to a specific NDA or ANDA?
Orange Book status depends on FDA patent listings for the specific product and Orange Book database entries, which are not provided in the prompt.
References
- US 9,549,909 claim set provided in the prompt.
